124 related articles for article (PubMed ID: 38537439)
1. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.
Chen X; Zhu N; Wu Y; Zhang Y; Zhang Y; Jin K; Zhou Z; Chen G; Wang J
Phytomedicine; 2024 Jun; 128():155317. PubMed ID: 38537439
[TBL] [Abstract][Full Text] [Related]
2. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
5. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis.
Tang Q; Ren L; Liu J; Li W; Zheng X; Wang J; Du G
Cell Prolif; 2020 Jan; 53(1):e12706. PubMed ID: 31642559
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
[TBL] [Abstract][Full Text] [Related]
7. Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.
Chen W; Zou P; Zhao Z; Weng Q; Chen X; Ying S; Ye Q; Wang Z; Ji J; Liang G
Oncotarget; 2016 Mar; 7(13):16593-609. PubMed ID: 26919094
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.
Niu B; Wei S; Sun J; Zhao H; Wang B; Chen G
Pharm Biol; 2022 Dec; 60(1):75-86. PubMed ID: 34962429
[TBL] [Abstract][Full Text] [Related]
9. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Yao X; Zhao CR; Yin H; Wang K; Gao JJ
Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
[TBL] [Abstract][Full Text] [Related]
11. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
13. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
Yin C; Dai X; Huang X; Zhu W; Chen X; Zhou Q; Wang C; Zhao C; Zou P; Liang G; Rajamanickam V; Wang O; Zhang X; Cui R
J Cell Mol Med; 2019 Mar; 23(3):2194-2206. PubMed ID: 30609207
[TBL] [Abstract][Full Text] [Related]
14. Curcuminoid WZ26, a TrxR1 inhibitor, effectively inhibits colon cancer cell growth and enhances cisplatin-induced cell death through the induction of ROS.
Zhang T; Zheng P; Shen X; Shao R; Wang B; Shen H; Zhang J; Xia Y; Zou P
Free Radic Biol Med; 2019 Sep; 141():93-102. PubMed ID: 31176737
[TBL] [Abstract][Full Text] [Related]
15. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.
Zheng Y; Zhou Q; Zhao C; Li J; Yu Z; Zhu Q
J Cell Mol Med; 2021 Feb; 25(3):1468-1479. PubMed ID: 33393219
[TBL] [Abstract][Full Text] [Related]
16. Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity.
Zheng X; Ma W; Sun R; Yin H; Lin F; Liu Y; Xu W; Zeng H
Redox Biol; 2018 Apr; 14():237-249. PubMed ID: 28965082
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
Jiang C; Xu R; Li XX; Zhou YF; Xu XY; Yang Y; Wang HY; Zheng XFS
Mol Cancer Ther; 2018 Dec; 17(12):2610-2621. PubMed ID: 30224431
[TBL] [Abstract][Full Text] [Related]
18. Glaucocalyxin A impairs tumor growth via amplification of the ATF4/CHOP/CHAC1 cascade in human oral squamous cell carcinoma.
Wang X; He MJ; Chen XJ; Bai YT; Zhou G
J Ethnopharmacol; 2022 May; 290():115100. PubMed ID: 35151835
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
